Skip to main content
Erschienen in: Journal of Gastroenterology 1/2024

22.11.2023 | Original Article—Alimentary Tract

Lansoprazole inhibits the development of sessile serrated lesions by inducing G1 arrest via Skp2/p27 signaling pathway

verfasst von: Tomoyuki Kawaguchi, Koichi Okamoto, Shota Fujimoto, Masahiro Bando, Hironori Wada, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma, Katsuhisa Horimoto, Tetsuji Takayama

Erschienen in: Journal of Gastroenterology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Although the serrated-neoplasia pathway reportedly accounts for 15–30% of colorectal cancer (CRC), no studies on chemoprevention of sessile serrated lesions (SSLs) have been reported. We searched for effective compounds comprehensively from a large series of compounds by employing Connectivity Map (CMAP) analysis of SSL-specific gene expression profiles coupled with in vitro screening using SSL patient-derived organoids (PDOs), and validated their efficacy using a xenograft mouse model of SSL.

Methods

We generated SSL-specific gene signatures based on DNA microarray data, and applied them to CMAP analysis with 1309 FDA-approved compounds to select candidate compounds. We evaluated their inhibitory effects on SSL-PDOs using a cell viability assay. SSL-PDOs were orthotopically transplanted into NOG mice for in vivo evaluation. The signal transduction pathway was evaluated by gene expression profile and protein expression analysis.

Results

We identified 221 compounds by employing CMAP analysis of SSL-specific signatures, which should cancel the gene signatures, and narrowed them down to 17 compounds. Cell viability assay using SSL-PDOs identified lansoprazole as having the lowest IC50 value (47 µM) among 17 compounds. When SSL-PDO was orthotopically transplanted into murine intestinal tract, the tumor grew gradually. Administration of lansoprazole to mice inhibited the growth of SSL xenograft whereas the tumor in control mice treated with vehicle alone grew gradually over time. The Ki67 index in xenograft lesions from the lansoprazole group was significantly lower compared with the control group. Cell cycle analysis of SSL-PDOs treated with lansoprazole exhibited a significant increase in G1 phase cell population. Microarray and protein analysis revealed that lansoprazole downregulated Skp2 expression and upregulated p27 expression in SSL-PDOs.

Conclusions

Our data strongly suggest that lansoprazole is the most effective chemopreventive agent against SSL, and that lansoprazole induces G1 cell cycle arrest by downregulating Skp2 and upregulating p27 in SSL cells.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMed Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMed
2.
Zurück zum Zitat Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–32.PubMed Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–32.PubMed
3.
Zurück zum Zitat Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138:2088–100.PubMed Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138:2088–100.PubMed
4.
Zurück zum Zitat Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011;42:1–10.PubMed Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011;42:1–10.PubMed
5.
Zurück zum Zitat Sweetser S, Smyrk TC, Sinicrope FA. Serrated colon polyps as precursors to colorectal cancer. Clin Gastroenterol Hepatol. 2013;11:760–7.PubMed Sweetser S, Smyrk TC, Sinicrope FA. Serrated colon polyps as precursors to colorectal cancer. Clin Gastroenterol Hepatol. 2013;11:760–7.PubMed
6.
Zurück zum Zitat Sugai T, Habano W, Takagi R, et al. Analysis of molecular alterations in laterally spreading tumors of the colorectum. J Gastroenterol. 2017;52:715–23.PubMed Sugai T, Habano W, Takagi R, et al. Analysis of molecular alterations in laterally spreading tumors of the colorectum. J Gastroenterol. 2017;52:715–23.PubMed
7.
Zurück zum Zitat Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113–30.PubMed Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113–30.PubMed
8.
Zurück zum Zitat Pai RK, Mäkinen MJ M, Rosty C. Colorectal serrated lesions and polyps. In: WHO classification of tumours editorial board (Ed.) WHO classification of tumours of the digestive system IARC, Lyon. 2019 pp.163–9. Pai RK, Mäkinen MJ M, Rosty C. Colorectal serrated lesions and polyps. In: WHO classification of tumours editorial board (Ed.) WHO classification of tumours of the digestive system IARC, Lyon. 2019 pp.163–9.
9.
Zurück zum Zitat Kambara T. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut. 2004;53:1137–44.PubMedPubMedCentral Kambara T. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut. 2004;53:1137–44.PubMedPubMedCentral
10.
Zurück zum Zitat Higuchi T, Sugihara K, Jass JR. Demographic and pathological characteristics of serrated polyps of colorectum. Histopathology. 2005;47:32–40.PubMed Higuchi T, Sugihara K, Jass JR. Demographic and pathological characteristics of serrated polyps of colorectum. Histopathology. 2005;47:32–40.PubMed
11.
Zurück zum Zitat O’Brien MJ, Yang S, Mack C, et al. Comparison of microsatellite instability, CpG Island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol. 2006;30:1491–501.PubMed O’Brien MJ, Yang S, Mack C, et al. Comparison of microsatellite instability, CpG Island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol. 2006;30:1491–501.PubMed
12.
Zurück zum Zitat Rosty C, Hewett DG, Brown IS, et al. Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management. J Gastroenterol. 2013;48:287–302.PubMed Rosty C, Hewett DG, Brown IS, et al. Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management. J Gastroenterol. 2013;48:287–302.PubMed
13.
Zurück zum Zitat Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–6.PubMedPubMedCentral Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–6.PubMedPubMedCentral
14.
Zurück zum Zitat Aderka D, Stintzing S, Heinemann V. Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. Lancet Oncol. 2019;20:e274–83.PubMed Aderka D, Stintzing S, Heinemann V. Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. Lancet Oncol. 2019;20:e274–83.PubMed
15.
Zurück zum Zitat Lenz H-J, Ou F-S, Venook AP, et al. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2019;37:1876–85.PubMedPubMedCentral Lenz H-J, Ou F-S, Venook AP, et al. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2019;37:1876–85.PubMedPubMedCentral
16.
Zurück zum Zitat Wallace K, Grau MV, Ahnen D, et al. The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum. Cancer Epidemiol Biomarkers Prev. 2009;18:2310–7.PubMedPubMedCentral Wallace K, Grau MV, Ahnen D, et al. The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum. Cancer Epidemiol Biomarkers Prev. 2009;18:2310–7.PubMedPubMedCentral
17.
Zurück zum Zitat Jass JR, Whitehall VL, Young J, et al. Emerging concepts in colorectal neoplasia. Gastroenterology. 2002;123:862–76.PubMed Jass JR, Whitehall VL, Young J, et al. Emerging concepts in colorectal neoplasia. Gastroenterology. 2002;123:862–76.PubMed
18.
Zurück zum Zitat Lamb J. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929–35.PubMed Lamb J. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929–35.PubMed
19.
Zurück zum Zitat Jin L, Tu J, Jia J, et al. Drug-repurposing identified the combination of trolox C and cytisine for the treatment of type 2 diabetes. J Transl Med. 2014;12:153.PubMedPubMedCentral Jin L, Tu J, Jia J, et al. Drug-repurposing identified the combination of trolox C and cytisine for the treatment of type 2 diabetes. J Transl Med. 2014;12:153.PubMedPubMedCentral
20.
Zurück zum Zitat Shigemizu D, Hu Z, Hung J-H, et al. Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS Comput Biol. 2012;8: e1002347.PubMedPubMedCentral Shigemizu D, Hu Z, Hung J-H, et al. Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS Comput Biol. 2012;8: e1002347.PubMedPubMedCentral
21.
Zurück zum Zitat Musa A, Ghoraie LS, Zhang S-D, et al. A review of connectivity map and computational approaches in pharmacogenomics. Brief Bioinform. 2018;19:506–23.PubMed Musa A, Ghoraie LS, Zhang S-D, et al. A review of connectivity map and computational approaches in pharmacogenomics. Brief Bioinform. 2018;19:506–23.PubMed
22.
Zurück zum Zitat Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology. 2011;141:1762–72.PubMed Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology. 2011;141:1762–72.PubMed
23.
Zurück zum Zitat Sugimoto S, Ohta Y, Fujii M, et al. Reconstruction of the human colon epithelium in vivo. Cell Stem Cell. 2018;22(171–6): e5. Sugimoto S, Ohta Y, Fujii M, et al. Reconstruction of the human colon epithelium in vivo. Cell Stem Cell. 2018;22(171–6): e5.
24.
Zurück zum Zitat Kagamu H, Kitano S, Yamaguchi O, et al. CD4(+) T-cell immunity in the peripheral blood correlates with response to anti-PD-1 therapy. Cancer Immunol Res. 2020;8:334–44.PubMed Kagamu H, Kitano S, Yamaguchi O, et al. CD4(+) T-cell immunity in the peripheral blood correlates with response to anti-PD-1 therapy. Cancer Immunol Res. 2020;8:334–44.PubMed
25.
Zurück zum Zitat Kosaka T, Nagamatsu G, Saito S, et al. Identification of drug candidate against prostate cancer from the aspect of somatic cell reprogramming. Cancer Sci. 2013;104:1017–26.PubMedPubMedCentral Kosaka T, Nagamatsu G, Saito S, et al. Identification of drug candidate against prostate cancer from the aspect of somatic cell reprogramming. Cancer Sci. 2013;104:1017–26.PubMedPubMedCentral
26.
Zurück zum Zitat Wada H, Sato Y, Fujimoto S, et al. Resveratrol inhibits development of colorectal adenoma via suppression of LEF1; comprehensive analysis with connectivity map. Cancer Sci. 2022;113:4374–84.PubMedPubMedCentral Wada H, Sato Y, Fujimoto S, et al. Resveratrol inhibits development of colorectal adenoma via suppression of LEF1; comprehensive analysis with connectivity map. Cancer Sci. 2022;113:4374–84.PubMedPubMedCentral
27.
Zurück zum Zitat Takahashi S, Okamoto K, Tanahashi T, et al. S100P expression via DNA hypomethylation promotes cell growth in the sessile serrated adenoma/polyp-cancer sequence. Digestion. 2021;102:789–802.PubMed Takahashi S, Okamoto K, Tanahashi T, et al. S100P expression via DNA hypomethylation promotes cell growth in the sessile serrated adenoma/polyp-cancer sequence. Digestion. 2021;102:789–802.PubMed
28.
Zurück zum Zitat Singh M, Dhindsa G, Friedland S, et al. Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas. Aliment Pharmacol Ther. 2007;26:1051–61.PubMed Singh M, Dhindsa G, Friedland S, et al. Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas. Aliment Pharmacol Ther. 2007;26:1051–61.PubMed
29.
Zurück zum Zitat Johnson CC, Hayes RB, Schoen RE, et al. Non-steroidal anti-inflammatory drug use and colorectal polyps in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Gastroenterol. 2010;105:2646–55.PubMedPubMedCentral Johnson CC, Hayes RB, Schoen RE, et al. Non-steroidal anti-inflammatory drug use and colorectal polyps in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Gastroenterol. 2010;105:2646–55.PubMedPubMedCentral
30.
Zurück zum Zitat Carragher LA, Snell KR, Giblett SM, et al. V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med. 2010;2:458–71.PubMedPubMedCentral Carragher LA, Snell KR, Giblett SM, et al. V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med. 2010;2:458–71.PubMedPubMedCentral
31.
Zurück zum Zitat Sakamoto N, Feng Y, Stolfi C, et al. BRAF(V600E) cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis. Elife. 2017;6:e20331.PubMedPubMedCentral Sakamoto N, Feng Y, Stolfi C, et al. BRAF(V600E) cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis. Elife. 2017;6:e20331.PubMedPubMedCentral
32.
Zurück zum Zitat Lannagan TRM, Lee YK, Wang T, et al. Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. Gut. 2019;68:684–92.PubMed Lannagan TRM, Lee YK, Wang T, et al. Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. Gut. 2019;68:684–92.PubMed
33.
Zurück zum Zitat Bond CE, Liu C, Kawamata F, et al. Oncogenic BRAF mutation induces DNA methylation changes in a murine model for human serrated colorectal neoplasia. Epigenetics. 2018;13:40–8.PubMedPubMedCentral Bond CE, Liu C, Kawamata F, et al. Oncogenic BRAF mutation induces DNA methylation changes in a murine model for human serrated colorectal neoplasia. Epigenetics. 2018;13:40–8.PubMedPubMedCentral
34.
Zurück zum Zitat Shimokawa M, Ohta Y, Nishikori S, et al. Visualization and targeting of LGR5(+) human colon cancer stem cells. Nature. 2017;545:187–92.PubMed Shimokawa M, Ohta Y, Nishikori S, et al. Visualization and targeting of LGR5(+) human colon cancer stem cells. Nature. 2017;545:187–92.PubMed
35.
Zurück zum Zitat Kikuchi H, Kato H, Mizuno M, et al. Differences in inducibility of CYP1A1-mRNA by benzimidazole compounds between human and mouse cells: evidences of a human-specific signal transduction pathway for CYP1A1 induction. Arch biochem biophys. 1996;334:235–40.PubMed Kikuchi H, Kato H, Mizuno M, et al. Differences in inducibility of CYP1A1-mRNA by benzimidazole compounds between human and mouse cells: evidences of a human-specific signal transduction pathway for CYP1A1 induction. Arch biochem biophys. 1996;334:235–40.PubMed
36.
Zurück zum Zitat Hume S, Grou CP, Lascaux P, et al. The NUCKS1-SKP2-p21/p27 axis controls S phase entry. Nat Commun. 2021;12:6959.PubMedPubMedCentral Hume S, Grou CP, Lascaux P, et al. The NUCKS1-SKP2-p21/p27 axis controls S phase entry. Nat Commun. 2021;12:6959.PubMedPubMedCentral
37.
Zurück zum Zitat Luciani F, Spada M, De Milito A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96:1702–13.PubMed Luciani F, Spada M, De Milito A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96:1702–13.PubMed
38.
Zurück zum Zitat De Milito A, Canese R, Marino ML, et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2010;127:207–19.PubMed De Milito A, Canese R, Marino ML, et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2010;127:207–19.PubMed
39.
Zurück zum Zitat Patlolla JM, Zhang Y, Li Q, et al. Anti-carcinogenic properties of omeprazole against human colon cancer cells and azoxymethane-induced colonic aberrant crypt foci formation in rats. Int J Oncol. 2012;40:170–5.PubMed Patlolla JM, Zhang Y, Li Q, et al. Anti-carcinogenic properties of omeprazole against human colon cancer cells and azoxymethane-induced colonic aberrant crypt foci formation in rats. Int J Oncol. 2012;40:170–5.PubMed
40.
Zurück zum Zitat Zhang S, Wang Y, Li SJ. Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion. Biochem Biophys Res Commun. 2014;448:424–9.PubMed Zhang S, Wang Y, Li SJ. Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion. Biochem Biophys Res Commun. 2014;448:424–9.PubMed
41.
Zurück zum Zitat Zeng X, Liu L, Zheng M, et al. Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase. Oncotarget. 2016;7:22460–73.PubMedPubMedCentral Zeng X, Liu L, Zheng M, et al. Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase. Oncotarget. 2016;7:22460–73.PubMedPubMedCentral
42.
Zurück zum Zitat Zhao X, Zhang N, Huang Y, et al. Lansoprazole alone or in combination with gefitinib shows antitumor activity against non-small cell lung cancer A549 cells in vitro and in vivo. Front Cell Dev Biol. 2021;9: 655559.PubMedPubMedCentral Zhao X, Zhang N, Huang Y, et al. Lansoprazole alone or in combination with gefitinib shows antitumor activity against non-small cell lung cancer A549 cells in vitro and in vivo. Front Cell Dev Biol. 2021;9: 655559.PubMedPubMedCentral
43.
Zurück zum Zitat He X, Hang D, Wu K, et al. Long-term risk of colorectal cancer after removal of conventional adenomas and serrated polyps. Gastroenterology. 2020;158(852–61): e4. He X, Hang D, Wu K, et al. Long-term risk of colorectal cancer after removal of conventional adenomas and serrated polyps. Gastroenterology. 2020;158(852–61): e4.
44.
Zurück zum Zitat Muller C, Yamada A, Ikegami S, et al. Risk of colorectal cancer in serrated polyposis syndrome: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20:622–30.PubMed Muller C, Yamada A, Ikegami S, et al. Risk of colorectal cancer in serrated polyposis syndrome: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20:622–30.PubMed
45.
Zurück zum Zitat Ohki D, Yamamichi N, Sakaguchi Y, et al. Transcriptome of sessile serrated adenoma/polyps is associated with MSI-high colorectal cancer and decreased expression of CDX2. Cancer Med. 2022;11:5066–78.PubMedPubMedCentral Ohki D, Yamamichi N, Sakaguchi Y, et al. Transcriptome of sessile serrated adenoma/polyps is associated with MSI-high colorectal cancer and decreased expression of CDX2. Cancer Med. 2022;11:5066–78.PubMedPubMedCentral
Metadaten
Titel
Lansoprazole inhibits the development of sessile serrated lesions by inducing G1 arrest via Skp2/p27 signaling pathway
verfasst von
Tomoyuki Kawaguchi
Koichi Okamoto
Shota Fujimoto
Masahiro Bando
Hironori Wada
Hiroshi Miyamoto
Yasushi Sato
Naoki Muguruma
Katsuhisa Horimoto
Tetsuji Takayama
Publikationsdatum
22.11.2023
Verlag
Springer Nature Singapore
Erschienen in
Journal of Gastroenterology / Ausgabe 1/2024
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-023-02052-0

Weitere Artikel der Ausgabe 1/2024

Journal of Gastroenterology 1/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.